Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure

Journal of Cardiovascular Medicine

Volumn 16, Issue 9, 2015, Pages 591-596

  El Refai, Mostafa ^a   Hrobowski, Tara ^b   Peterson, Edward L ^c   Wells, Karen ^c   Spertusd, John A ^d   Williams, L Keoki ^c   Lanfear, David E ^a,b,c  

^a Department of Internal Medicine ^*  (United States)

^b Heart and Vascular Institute   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Heart failure; Hospitalization; Outcomes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AFRICAN AMERICAN; ARTICLE; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RACE; RETROSPECTIVE STUDY; AGED; CAUCASIAN; EPIDEMIOLOGY; ETHNOLOGY; MICHIGAN; MIDDLE AGED; PROGNOSIS; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MICHIGAN; MIDDLE AGED; PATIENT READMISSION; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942818396     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000091     Document Type: Article

References (26)

1. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics - 2013 update - a report from the American Heart Association. Circulation 2013; 127: 143-152.
2. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002; 39: 60-69.
3. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018.
4. Mitchell JE, Ferdinand KC, Watson KE, et al. Treatment of heart failure in African Americans: a call to action. J Natl Med Assoc 2011; 103: 86-98.
5. Bagchi AD, Stewart K, McLaughlin C, Higgins P, Croghan T. Treatment and outcomes for congestive heart failure by race/ethnicity in TRICARE. Med Care 2011; 49: 489-495.
6. Franciosa JA, Ferdinand KC, Yancy CW. Treatment of heart failure in African Americans: a consensus statement. Congest Heart Fail 2010; 16: 27-38.
7. Yancy CW. Heart failure in African Americans. Am J Cardiol 2005; 96: 3i-12i.
8. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-1435.
9. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
10. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-691.
11. Cleland JG, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985; 54: 305-312.
12. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
13. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines - developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479.
14. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010; 16: e1-e194.
15. Wallace TW, Drazner MH. The impact of race on response to RAAS inhibition. Curr Heart Fail Rep 2005; 2: 72-77.
16. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5: 178-187.
17. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340: 609-616.
18. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344: 1351-1357.
19. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensinconverting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002; 40: 311-317.
20. Alqaisi F, Williams LK, Peterson EL, Lanfear DE. Comparing methods for identifying patients with heart failure using electronic data sources. BMC Health Serv Res 2009; 9: 237.
21. Lee WY, Capra AM, Jensvold NG, Gurwitz JH, Go AS. Gender and risk of adverse outcomes in heart failure. Am J Cardiol 2004; 94: 1147-1152.
22. Yang JJ, Burchard EG, Choudhry S, et al. Differences in allergic sensitization by self-reported race and genetic ancestry. J Allergy Clin Immunol 2008; 122: 820-827; e9.
23. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366: 2005-2011.
24. Fleiss JL, Levin BA, Paik MC. Statistical methods for rates and proportions, 3rd ed. Hoboken, NJ: J. Wiley; 2003.
25. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-1538.
26. Schulz A, Israel B, Williams D, Parker E, Becker A, James S. Social inequalities, stressors and self reported health status among African American and white women in the Detroit metropolitan area. Soc Sci Med 2000; 51: 1639-1653.